Le Lézard
Classified in: Ebola virus, Health
Subjects: TDS, FVT

Tru-D SmartUVC to Attend and Exhibit at IDWeek 2017



SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- The first and only UV disinfection robot validated by a CDC-funded randomized clinical trial, Tru-D SmartUVC will attend and exhibit at IDWeek, October 4-8, 2017 in San Diego, California. Tru-D invites IDWeek attendees to its booth #647 to learn how its technology provides thorough room disinfection, reduces the risk of hospital-acquired infections (HAIs) and makes health care facilities cleaner and safer for patients and staff.

IDWeek is the combined annual meeting of the IDSA, SHEA, HIVMA and PIDS, where infectious disease professionals are able to meet, share experiences and collaborate for the improvement of patient care and public health. Geared toward health care professionals in infectious diseases and health care epidemiology and prevention, the conference is critical for those who want to stay current in the latest trends and technologies for excellence in patient care.

"Tru-D's technology has been validated by more than a dozen third-party studies to show that it is capable of providing thorough room disinfection from one position in the room," said Chuck Dunn, CEO and President of Tru-D SmartUVC. "The pioneer of the UV disinfection space, Tru-D continues to drive innovation and acceptance of UV disinfection technology to help keep health care environments safer for the next patient who enters a room."

An automated, no-touch disinfection robot, Tru-D is brought in to a room after the environmental services (ES) staff cleans using traditional methods. Tru-D then operates from one position in the room and administers one cycle of UVC light, destroying up to 99.9 percent of harmful pathogens that can remain behind such as C. diff, MRSA, MERS, VRE, Ebola and many more. Once the cycle is finished, Tru-D alerts the operator via audio and/or text message that disinfection is complete, and Tru-D can be moved to the next room. Tru-D also delivers disinfection data to a secure myTru-D portal, allowing for real time documentation of the disinfection process, putting critical data directly in the hands of operators and administrators.

Tru-D was the only device of its kind selected for the first randomized clinical trial on UVC disinfection because of its Sensor360 technology that precisely measures the proper UV dose needed for every room, eliminating any chance for human error in the disinfection process. Results of the CDC-funded Benefits of Enhanced Terminal Room Disinfection (BETR-D) study proved that enhanced disinfection strategies that utilized Tru-D reduced the risk of acquisition and infection of four major superbugs by a cumulative 30 percent among patients who entered the same room.

Tru-D invites attendees to its booth #647 to learn more about how it reduces the risk of infections and improves patient outcomes. For more information, visit Tru-D.com.

About Tru-D SmartUVC
Only Tru-D delivers an automated, measured dose of UVC light to consistently disinfect an entire room during a single cycle. Operating from a single position in the room, Tru-D ensures significant pathogen reduction in direct and shadowed areas. Validated by more than a dozen independent studies, Tru-D's automated, measured dosing capabilities and real-time usage-tracking features make it one of the most advanced UV disinfection systems available.

Christin Yates                                  
Public Relations                             
Tru-D SmartUVC                            
901-774-5771                                 
177802@email4pr.com

SOURCE Tru-D SmartUVC


These press releases may also interest you

at 18:15
At a November meeting of business leaders in Wisconsin, Mike Clumpner, Chairman of privately held Nova Molecular Technologies discussed how Nova has quickly achieved a sustainable and advantaged position as one of the world's largest manufacturers of...

at 18:11
The Alliance to Fight the 40 | Don't Tax My Health Care today applauded Congressional leaders for including a two-year delay of the 40% "Cadillac Tax" in their bill to end the government shutdown and provide funding through February 8th. This...

at 17:21
Frost & Sullivan's latest analysis of the European prenatal genetic testing market point to advancements in technologies, such as next-generation sequencing techniques (NGS) and use of non-invasive prenatal testing (NIPT), as the key factors...

at 17:17
Stanton Optical, known for delivering the highest quality products and services for customers in eyewear, sunglasses, and contact lenses at affordable prices, is opening a new optical store in Boynton Beach, Florida in early February. This will bring...

at 17:04
Arena Pharmaceuticals, Inc. , today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate (S1P) receptor modulation in the treatment of autoimmune diseases in New York City on Monday, January...

at 17:00
Community Healthcare Trust Incorporated today announced that on Thursday evening, February 22, 2018, after the market closes, it will report results for the fourth quarter of 2017.  On February 23, 2018, at 9:00 a.m. Central Time, Community...




News published on 26 september 2017 at 08:30 and distributed by: